Azilsartan reduced TNF-α and IL-1β levels, increased IL-10 levels and upregulated VEGF, FGF, KGF, and TGF-α in an oral mucositis model

dc.contributor.authorAraújo, Aurigena Antunes de
dc.contributor.authorVarela, Hugo
dc.contributor.authorMedeiros, Caroline Addison Carvalho Xavier de
dc.contributor.authorBrito, Gerly Anne de Castro
dc.contributor.authorLima, Kenio Costa de
dc.contributor.authorMoura, Ligia Moreno de
dc.contributor.authorAraújo Júnior, Raimundo Fernandes de
dc.date.accessioned2017-05-16T12:16:35Z
dc.date.available2017-05-16T12:16:35Z
dc.date.issued2015
dc.description.resumoOral mucositis (OM) is a common complication of treatments for head and neck cancer, particularly radiotherapy with or without chemotherapy. OM is characterised by oral erythema, ulceration, and pain. The aim of this study was to evaluate the effect of azilsartan (AZT), an angiotensin II receptor antagonist, on 5-fluorouracil (5-FU)-induced oral mucositis (OM) in Syrian hamsters. OM was induced by the intraperitoneal administration of 5-FU on experimental days 1 (60 mg/Kg) and 2 (40 mg/Kg). Animals were pretreated with oral AZT (1, 5, or 10 mg/kg) or vehicle 30 min before 5-FU injection and daily until day 10. Experimental treatment protocols were approved by the Animal Ethics Committee Use/CEUA (Number 28/2012) of the UFRN. Macroscopic analysis and cheek pouch samples were removed for histopathologic analysis. Myeloperoxidase (MPO), Malonyldialdehyde (MDA), interleukin-1 beta (IL-1β), interleukin-10 (IL-10), and tumour necrosis factor-alpha (TNF-α) were analysed by Enzyme Linked Immuno Sorbent Assay (ELISA). Vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), keratinocyte growth factor (KGF), and transforming growth factor (TGF)-α were measured by immunohistochemistry. Analysis of variance followed by Bonferroni's test was used to calculate the means of intergroup differences (p ≤ 0.05). Treatment with 1 mg/kg AZT reduced levels MPO (p<0.01), MDA (p<0.5) and histological inflammatory cell infiltration, and increased the presence of granulation tissue. AZT treatment at 1 mg/kg reduced the TNF-α (p<0.05) and IL-1β (p<0.05) levels, increased the cheek pouch levels of IL-10 (p<0.01), and upregulated VEGF, FGF, KGF, and TGF-α. Administration of AZT at higher doses (5 and 10 mg/kg) did not significantly reverse the OM. AZT at a dose of 1 mg/kg prevented the mucosal damage and inflammation associated with 5-FU-induced OM, increasing granulation and tissue repair.pt_BR
dc.identifier.citationARAÚJO, Aurigena Antunes de et al. Azilsartan reduced TNF-α and IL-1β levels, increased IL-10 levels and upregulated VEGF, FGF, KGF, and TGF-α in an oral mucositis model. Plos One, v. 10, n. 2, p. e0116799, 2015.pt_BR
dc.identifier.urihttps://repositorio.ufrn.br/jspui/handle/123456789/22927
dc.languageengpt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectLymphotoxin-alphapt_BR
dc.subjectInterleukin-10pt_BR
dc.subjectReceptors, Fibroblast Growth Factorpt_BR
dc.subjectStomatitispt_BR
dc.titleAzilsartan reduced TNF-α and IL-1β levels, increased IL-10 levels and upregulated VEGF, FGF, KGF, and TGF-α in an oral mucositis modelpt_BR
dc.typearticlept_BR

Arquivos

Pacote Original

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
AzilsartanReduced_Araujo_2015.PDF
Tamanho:
15.65 MB
Formato:
Adobe Portable Document Format
Descrição:
https://www.ncbi.nlm.nih.gov/pubmed/25689279
Nenhuma Miniatura disponível
Baixar

Licença do Pacote

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.53 KB
Formato:
Item-specific license agreed upon to submission
Nenhuma Miniatura disponível
Baixar